This intellectual property portfolio from Stanford inventors features a diverse collection of bioconjugates and antibody-drug conjugates. These technologies encompass a range of applications, from enabling selective cytotoxicity for cancer treatment to advanced imaging and detection tools, opening up new avenues for targeted therapeutic interventions. The portfolio also includes novel conjugate design and engineering methods, providing a foundation for the development of next-generation targeted therapies with the potential to improve patient outcomes.